Neuropsychological and Behavioral Testing in Younger Patients With Cancer

a study on Malignant Neoplasm Neoplasms

Summary

Eligibility
for people ages 1 month and up (full criteria)
Location
at Oakland, California and other locations
Dates
study started
Principal Investigator
by Carla B. GoldenAnuradha Banerjee
Headshot of Carla B. Golden
Carla B. Golden
Headshot of Anuradha Banerjee
Anuradha Banerjee

Description

Summary

This research trial studies neuropsychological (learning, remembering or thinking) and behavioral outcomes in children and adolescents with cancer by collecting information over time from a series of tests.

Official Title

Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer

Details

PRIMARY OBJECTIVES:

  1. To institute procedures to ensure a consistent, streamlined, and efficient administration of the neuropsychological/behavioral tests in a cooperative group setting in order to maximize compliance with a standardized assessment battery conducted at 3 standardized time points.

OUTLINE:

Parent and child participants complete the COG Standard Neuropsychological and Behavioral Battery at approximately 9, 30, and 60 months post-diagnosis in a 1-2 hour testing session conducted by a neuropsychologist or psychologist. The Battery consists of measures of intelligence, processing speed, attention, memory, language preference, behavioral/social/emotional function, executive function, adaptive function, and quality of life.

Keywords

Childhood Malignant Neoplasm, Neoplasms, Cognitive Assessment, Quality-of-Life Assessment

Eligibility

You can join if…

Open to people ages 1 month and up

  • The patient must be currently be enrolled or plan to be enrolled on a COG therapeutic study that aims to examine neuropsychological, social, emotional, and/or behavioral functioning
  • The patient must have receptive and expressive language skills in English, French, or Spanish; if a patient meets these criteria but the parent/guardian speaks a language other than English, French, or Spanish, the patient may still be enrolled and tested, and the parent-report measures should be omitted
  • All patients and/or their parents or legal guardians must sign a written informed consent
  • All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

You CAN'T join if...

  • Patients with a history of moderate to profound intellectual disability (i.e. intelligence quotient [IQ] =< 55) are not eligible for enrollment; PLEASE NOTE: Children with a prior history of attention deficit hyperactivity disorder (ADHD) or a specific learning disability (e.g., dyslexia) are eligible for this study

Locations

  • Children's Hospital and Research Center at Oakland accepting new patients
    Oakland California 94609-1809 United States
  • UCSF Medical Center-Parnassus in progress, not accepting new patients
    San Francisco California 94143 United States
  • UCSF Medical Center-Mission Bay accepting new patients
    San Francisco California 94158 United States
  • Kaiser Permanente-Oakland accepting new patients
    Oakland California 94611 United States
  • Valley Children's Hospital accepting new patients
    Madera California 93636 United States
  • Lucile Packard Children's Hospital Stanford University accepting new patients
    Palo Alto California 94304 United States

Lead Scientists at UCSF

  • Carla B. Golden
    Professor, Pediatrics, School of Medicine. Authored (or co-authored) 9 research publications
  • Anuradha Banerjee
    Professor, Pediatrics, School of Medicine. Authored (or co-authored) 69 research publications

Details

Status
accepting new patients
Start Date
Sponsor
Children's Oncology Group
ID
NCT00772200
Study Type
Observational
Participants
Expecting 1200 study participants
Last Updated
Contact us about this trial